Anna Chang1,2, Marta Ruiz-Lopez1, Elizabeth Slow1, Mark Tarnopolsky3, Anthony E Lang1, Renato P Munhoz1. 1. Morton and Gloria Shulman Movement Disorders Clinic, Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology University of Toronto Toronto Ontario Canada. 2. Department of Neurology Shin Kong Wu Ho-Su Memorial Hospital Taipei Taiwan. 3. Department of Pediatrics and Neuromuscular and Neurometabolic Clinic McMaster University Medical Center Hamilton Ontario Canada.
Abstract
BACKGROUND: Disorders related to dysfunction of coenzyme (CoQ10) metabolism, including AarF domain containing kinase 3 gene (ADCK3) mutations, have received attention due to the potential for response to CoQ10 supplementation. METHODS: We describe two new cases of neurological syndromes due to ADCK3 mutations that obtained striking benefit from CoQ10, and a third who did not. We also review 20 cases from the literature in which responses to CoQ10 were documented out of all 38 previously reported cases. RESULTS: Despite the remarkable responses in some cases with ataxia and movement disorders (myoclonus, dystonia, tremor), overall, we were not able to identify variables that predicted response to CoQ10 supplementation. CONCLUSIONS: Based on our experience and data from the literature, we recommend a minimum of 10 mg/kg/day of ubiquinone with titration up to 15 mg/kg/day, maintained at least for 6 months in order to obtain or exclude potential benefit from therapy.
BACKGROUND: Disorders related to dysfunction of coenzyme (CoQ10) metabolism, including AarF domain containing kinase 3 gene (ADCK3) mutations, have received attention due to the potential for response to CoQ10 supplementation. METHODS: We describe two new cases of neurological syndromes due to ADCK3 mutations that obtained striking benefit from CoQ10, and a third who did not. We also review 20 cases from the literature in which responses to CoQ10 were documented out of all 38 previously reported cases. RESULTS: Despite the remarkable responses in some cases with ataxia and movement disorders (myoclonus, dystonia, tremor), overall, we were not able to identify variables that predicted response to CoQ10 supplementation. CONCLUSIONS: Based on our experience and data from the literature, we recommend a minimum of 10 mg/kg/day of ubiquinone with titration up to 15 mg/kg/day, maintained at least for 6 months in order to obtain or exclude potential benefit from therapy.
Authors: O Hikmat; C Tzoulis; P M Knappskog; S Johansson; H Boman; P Sztromwasser; E Lien; E Brodtkorb; D Ghezzi; L A Bindoff Journal: Eur J Neurol Date: 2016-04-23 Impact factor: 6.089
Authors: Rita Horvath; Birgit Czermin; Sweena Gulati; Stephanie Demuth; Gunnar Houge; Angela Pyle; Christine Dineiger; Emma L Blakely; Adam Hassani; Charlotte Foley; Michael Brodhun; Karin Storm; Janbernd Kirschner; Grainne S Gorman; Hanns Lochmüller; Elke Holinski-Feder; Robert W Taylor; Patrick F Chinnery Journal: J Neurol Neurosurg Psychiatry Date: 2011-10-29 Impact factor: 10.154
Authors: E Barca; O Musumeci; F Montagnese; S Marino; F Granata; D Nunnari; L Peverelli; S DiMauro; C M Quinzii; A Toscano Journal: Clin Genet Date: 2016-02-16 Impact factor: 4.438
Authors: Yo-Tsen Liu; Joshua Hersheson; Vincent Plagnol; Katherine Fawcett; Kate E C Duberley; Elisavet Preza; Iain P Hargreaves; Annapurna Chalasani; Matilde Laurá; Nick W Wood; Mary M Reilly; Henry Houlden Journal: J Neurol Neurosurg Psychiatry Date: 2013-11-11 Impact factor: 10.154
Authors: Andreas Traschütz; Tommaso Schirinzi; Lucia Laugwitz; Nathan H Murray; Craig A Bingman; Selina Reich; Jan Kern; Anna Heinzmann; Gessica Vasco; Enrico Bertini; Ginevra Zanni; Alexandra Durr; Stefania Magri; Franco Taroni; Alessandro Malandrini; Jonathan Baets; Peter de Jonghe; Willem de Ridder; Matthieu Bereau; Stephanie Demuth; Christos Ganos; A Nazli Basak; Hasmet Hanagasi; Semra Hiz Kurul; Benjamin Bender; Ludger Schöls; Ute Grasshoff; Thomas Klopstock; Rita Horvath; Bart van de Warrenburg; Lydie Burglen; Christelle Rougeot; Claire Ewenczyk; Michel Koenig; Filippo M Santorelli; Mathieu Anheim; Renato P Munhoz; Tobias Haack; Felix Distelmaier; David J Pagliarini; Hélène Puccio; Matthis Synofzik Journal: Ann Neurol Date: 2020-06-10 Impact factor: 11.274